Aurinia Pharmaceuticals (AUPH) Cost of Revenue: 2021-2025
Historic Cost of Revenue for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $8.2 million.
- Aurinia Pharmaceuticals' Cost of Revenue rose 35.49% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 4.72%. This contributed to the annual value of $28.2 million for FY2024, which is 99.66% up from last year.
- Latest data reveals that Aurinia Pharmaceuticals reported Cost of Revenue of $8.2 million as of Q3 2025, which was up 14.93% from $7.1 million recorded in Q2 2025.
- Over the past 5 years, Aurinia Pharmaceuticals' Cost of Revenue peaked at $8.9 million during Q2 2024, and registered a low of $48,000 during Q1 2021.
- In the last 3 years, Aurinia Pharmaceuticals' Cost of Revenue had a median value of $6.8 million in 2023 and averaged $6.0 million.
- In the last 5 years, Aurinia Pharmaceuticals' Cost of Revenue spiked by 1,741.33% in 2024 and then declined by 20.14% in 2025.
- Aurinia Pharmaceuticals' Cost of Revenue (Quarterly) stood at $481,000 in 2021, then soared by 183.16% to $1.4 million in 2022, then skyrocketed by 296.11% to $5.4 million in 2023, then grew by 2.91% to $5.6 million in 2024, then surged by 35.49% to $8.2 million in 2025.
- Its last three reported values are $8.2 million in Q3 2025, $7.1 million for Q2 2025, and $8.6 million during Q1 2025.